XTX Topco Ltd purchased a new position in Zymeworks Inc. (NYSE:ZYME - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 33,702 shares of the company's stock, valued at approximately $493,000.
Several other institutional investors also recently bought and sold shares of ZYME. China Universal Asset Management Co. Ltd. increased its holdings in Zymeworks by 6.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company's stock valued at $214,000 after buying an additional 940 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of Zymeworks by 781.5% during the fourth quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock valued at $25,000 after purchasing an additional 1,524 shares during the period. FMR LLC increased its position in shares of Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company's stock worth $42,000 after acquiring an additional 1,525 shares during the period. Stifel Financial Corp boosted its holdings in shares of Zymeworks by 2.1% in the third quarter. Stifel Financial Corp now owns 73,654 shares of the company's stock valued at $924,000 after purchasing an additional 1,540 shares during the period. Finally, Teacher Retirement System of Texas grew its position in shares of Zymeworks by 19.2% during the 4th quarter. Teacher Retirement System of Texas now owns 13,743 shares of the company's stock worth $201,000 after buying an additional 2,216 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.
Zymeworks Price Performance
Shares of ZYME stock traded down $0.04 during trading hours on Friday, reaching $12.48. The stock had a trading volume of 95,984 shares, compared to its average volume of 616,978. The firm has a 50-day simple moving average of $12.17 and a 200-day simple moving average of $13.51. The firm has a market capitalization of $868.04 million, a PE ratio of -8.32 and a beta of 1.18. Zymeworks Inc. has a twelve month low of $7.97 and a twelve month high of $17.70.
Insider Activity
In other news, Director Ecor1 Capital, Llc bought 468,356 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was acquired at an average price of $12.48 per share, for a total transaction of $5,845,082.88. Following the transaction, the director now directly owns 16,802,141 shares of the company's stock, valued at $209,690,719.68. This trade represents a 2.87 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have bought 1,350,347 shares of company stock worth $16,137,499 over the last 90 days. 1.92% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
ZYME has been the subject of a number of recent research reports. HC Wainwright boosted their price objective on shares of Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Monday, March 10th. Citigroup increased their price objective on shares of Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research note on Friday, March 7th. Finally, Lifesci Capital started coverage on shares of Zymeworks in a report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $21.00.
Read Our Latest Analysis on ZYME
About Zymeworks
(
Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Further Reading
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
